Skip to main content

Table 1 Patient characteristics

From: Risk factors of fracture following curettage for bone giant cell tumors of the extremities

Variable (n = 284)

No. of patients

Filler

Sex

 

PMMA bone cement alone (n = 124)

PMMA bone cement and allograft bone grafting (n = 81)

Allograft or hydroxyapatite grafting (n = 79)

Male

131 (46.1%)

58 (46.4%)

43 (53.1%)

30 (38.5%)

Female

153 (53.9%)

67 (53.6%)

38 (46.9%)

48 (61.5%)

Age (years)

 Median

30

30.7

28.4

29.5

 Interquartile range

23.2–40.3

26.0–42.2

21.9–38.3

21.5–40.8

Site

 Distal radius

21 (7.4%)

12 (9.7%)

1 (1.2%)

8 (10.1%)

 Proximal femur

13 (4.6%)

1 (0.8%)

5 (6.2%)

7 (8.9%)

 Distal femur

94 (33.1%)

56 (45.1%)

28 (34.6%)

10 (12.7%)

 Proximal tibia

95 (33.5%)

35 (28.2%)

37 (45.7%)

23 (29.1%)

 Distal tibia

16 (5.6%)

5 (4.0%)

4 (4.9%)

7 (8.9%)

 Proximal humerus

12 (4.2%)

8 (6.5%)

1 (1.2%)

3 (3.8%)

 Othersa

33 (11.6%)

8 (6.5%)

5 (6.2%)

20 (25.3%)

Campanacci classification

 Stage I

7 (2.5%)

1 (0.8%)

2 (2.5%)

4 (5.1%)

 Stage II

220 (77.5%)

101 (80.8%)

60 (74.1%)

59 (75.6%)

 Stage III

57 (20.1%)

23 (18.4%)

19 (23.5%)

15 (19.2%)

Pathological fracture at presentation

 No

267 (94.0%)

118 (94.4%)

80 (98.8%)

69 (88.5%)

 Yes

17 (6.0%)

7 (5.6%)

1 (1.2%)

9 (11.5%)

Denosumab administration

 No

254 (89.4%)

107 (85.6%)

76 (93.8%)

71 (91.0%)

 Yes

30 (10.6%)

18 (14.4%)

5 (6.2%)

7 (9.0%)

Previous surgery

 No

251 (88.4%)

109 (87.2%)

72 (88.9%)

70 (89.7%)

 Yes

33 (11.6%)

16 (12.8%)

9 (11.1%)

8 (10.3%)

Local adjuvant therapy

 No

37 (13.0%)

19 (15.2%)

2 (2.5%)

16 (20.5%)

 Yes

247 (87.0%)

106 (84.8%)

79 (97.5%)

62 (79.5%)

Fracture

 No

274 (96.5%)

116 (92.8%)

80 (98.8%)

78 (100%)

 Yes

10 (3.5%)

9 (7.2%)

1 (1.2%)

0

Local recurrence

 None

217 (76.4%)

102 (81.6%)

65 (80.3%)

51 (65.4%)

  ≥ 1

67 (23.6%)

23 (18.4%)

16 (19.8%)

27 (34.6%)

Follow-up (months)

 Median

86.5

83.2

94.5

88.3

 Interquartile range

50.3–118.8

45.8–101.9

63.6–133.0

45.3–144

  1. PMMA Polymethylmethacrylate
  2. aOther sites include the distal ulna (7), talus (6), distal humerus (6), calcaneus (3), cuboid (2), hand phalanges (2), foot phalanges (2), proximal ulna (2), proximal radius (1), proximal fibula (1), and metatarsal (1)